IP Library Granted Patent US 10,017,738
Granted Patent B2
US 10,017,738 · App. 13/832,419 · Granted Jul 10, 2018

ABCB5 positive mesenchymal stem cells as immunomodulators

Inventor: Markus H. Frank (Cambridge, MA)
Assignee: Children's Medical Center Corporation
C12N5/0625A61K35/36C12N5/0668
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,017,738
App. No.
13/832,419
Granted
Jul 10, 2018
Kind
B2
Abstract

The present invention is directed to purified preparations of dermal mesenchymal stem cells that are characterized by the cell surface expression of the ABCB5 P-glycoprotein. The cells may be used for any purpose that mesenchymal stem cells from other course are used. For instance they may be administered to treat an organ transplant recipient to improve allograft survival or as a treatment to patients with autoimmune diseases such as multiple sclerosis and rheumatoid arthritis.

Claims (10)

1. A method for reconstructing a damaged cornea, comprising, administering to a cornea of a subject having a damaged cornea an isolated preparation of ABCB5 positive dermal mesenchymal stem cells, wherein ABCB5 positive dermal cells comprise at least 95% of the isolated preparation of ABCB5 positive dermal mesenchymal stem cells.

2. The method of claim 1 , wherein the isolated preparation of ABCB5 positive dermal mesenchymal stem cells are seeded onto a matrix or scaffold.

3. The method of claim 2 , wherein the matrix is a polymeric mesh or sponge.

4. The method of claim 2 , wherein the matrix is a polymeric hydrogel.

5. The matrix of claim 2 , wherein the matrix is a collagen matrix.

6. The method of claim 1 , wherein ABCB5 positive dermal cells comprise at least 99% of the isolated preparation of ABCB5 positive dermal mesenchymal stem cells.

7. The method of claim 1 , wherein the ABCB5 positive dermal mesenchymal stem cells are autologous to the subject.

8. The method of claim 1 , wherein the ABCB5 positive dermal mesenchymal stem cells are non-autologous to the subject.

9. The method of claim 1 , wherein 1×10 7 -1×10 10 of the ABCB5 positive dermal mesenchymal stem cells are administered to the subject.

10. The method of claim 1 , wherein 1×10 8 -1×10 9 of the ABCB5 positive dermal mesenchymal stem cells are administered to the subject.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 29, 2013
From: FRANK, MARKUS H.
To: CHILDREN'S MEDICAL CENTER CORPORATION
Reel/Frame 030891/0964 →
Continuity (3)
Continuation 11809790 · May 31, 2007
Provisional Application 60809407 · May 31, 2006
Related Publication 20130315880A1 · Nov 28, 2013
Cited By (1)
US 12,448,461